Clinical Trials Logo

Clinical Trial Summary

This study is prospective ,open-label, single-center phase II clinical study. Target population is patients with advanced (stage III-IV) ovarian clear cell carcinoma. Study objective is to evaluate effectiveness response of Camrelizumab + anlotinib in subjects with advanced ovarian clear cell carcinoma Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.


Clinical Trial Description

In this study, eligible subjects were given a combination of carrelizumab and alozantinib at the same time, repeated every 21 days, during treatment based on imaging evaluation of the patient if disease progression, toxicity intolerance, or other reasons specified by the regimen could be terminated. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05600998
Study type Interventional
Source Peking University Third Hospital
Contact Hongyan Guo, Doctor
Phone +86 010-82267510
Email bysyghy@163.com
Status Not yet recruiting
Phase N/A
Start date October 30, 2022
Completion date February 28, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Recruiting NCT05296512 - Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer Phase 2
Completed NCT01914510 - A Study of ENMD-2076 in Ovarian Clear Cell Cancers Phase 2
Recruiting NCT04104776 - A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas Phase 1/Phase 2
Completed NCT03297424 - A Study of PLX2853 in Advanced Malignancies. Phase 1
Recruiting NCT03405454 - A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas Phase 2
Recruiting NCT06065462 - Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 Phase 1/Phase 2
Recruiting NCT05099978 - Asian Multicenter Prospective Study of ctDNA Sequencing
Not yet recruiting NCT05759312 - Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma Phase 1/Phase 2
Not yet recruiting NCT06279104 - A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary
Terminated NCT02837991 - A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma Phase 1
Recruiting NCT05498597 - AMT-151 in Patients With Selected Advanced Solid Tumours Phase 1
Recruiting NCT05226507 - A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer Phase 1
Recruiting NCT05281471 - Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) Phase 3
Recruiting NCT04735861 - Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma Phase 2
Recruiting NCT02866370 - Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Phase 2